Breaking News Instant updates and real-time market news.

SNAP

Snap

$20.27

0.37 (1.86%)

, WPM

Wheaton Precious Metals

$20.99

-0.4 (-1.87%)

08:45
05/19/17
05/19
08:45
05/19/17
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Snap Inc. (SNAP) 33.74% +1.07, (WPM) 1.27% +0.17, Northern Dynasty (NAK) 61.21% +0.12, Applied Optoelectronics (AAOI) 2.55% +0.03, CarMax (KMX) 0.63% +0.02, Sears (SHLD) 81.23% +0.01, and EXACT Sciences (EXAS) 0.79% +0.01.

SNAP

Snap

$20.27

0.37 (1.86%)

WPM

Wheaton Precious Metals

$20.99

-0.4 (-1.87%)

NAK

Northern Dynasty

$1.73

-0.06 (-3.35%)

AAOI

Applied Optoelectronics

$63.98

2.6 (4.24%)

KMX

CarMax

$63.71

3.69 (6.15%)

SHLD

Sears

$7.72

-0.24 (-3.02%)

EXAS

Exact Sciences

$31.03

0.7 (2.31%)

  • 22

    May

  • 24

    May

  • 30

    May

  • 06

    Jun

  • 29

    Jun

  • 30

    Jun

SNAP Snap
$20.27

0.37 (1.86%)

05/11/17
05/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Caterpillar (CAT) upgraded to Buy from Neutral at BofA/Merrill with analyst Ross Gilardi saying monthly retail sales continue to accelerate and views valuation as much more reasonable. Gilardi believes the company could have another big beat and raise in July and could raise the dividend over the summer. 2. Yum! Brands (YUM) upgraded to Neutral from Sell at Goldman Sachs with analyst Karen Holthouse saying her primary bear thesis, or continued weakness in China comps, has largely played out. She's increasingly positive on Taco Bell and sees limited near-term negative catalysts. 3. Symantec (SYMC) upgraded to Overweight from Equal-Weight at First Analysis with analyst Howard Smith saying he views the recent selloff as a buying opportunity and has increased confidence in the company's long-term growth following its fourth quarter results. 4. Snap (SNAP) upgraded to Outperform from Perform at Oppenheimer and to Neutral from Underweight at Cantor. 5. Electronic Arts (EA) upgraded to Buy from Hold at Ascendiant with analyst Edward Woo noting that the company's fourth quarter results beat expectations and he calls its guidance "strong." According to the analyst ,the company is benefiting from "strength in digital, growth in next gen consoles, and cost management." He calls its upcoming games "solid." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/11/17
JMPS
05/11/17
NO CHANGE
JMPS
Snap should be bought on weakness, says JMP Securities
JMP Securities analyst Ronald Josey says that Snap's engagement continues to increase, and he continues to believe that the company's ARPU can rise closer to that of Facebook (FB). The analyst recommends buying Snap on weakness and keeps a $28 price target on the stock.
05/11/17
LOOP
05/11/17
NO CHANGE
Target $18
LOOP
Hold
Snap lack of guidance likely to hurt investor confidence, says Loop Capital
Loop Capital analyst Blake Harper lowered his estimates for Snap Inc. and cut his price target to $18 from $21 following the company's report of Q1 revenues, adjusted EBITDA and DAUs that were below consensus estimates. The analyst, who keeps a Hold rating on Snap shares, added that the fact that management gave no financial guidance and no outlook for DAUs will likely diminish investor confidence.
05/11/17
OPCO
05/11/17
UPGRADE
Target $23
OPCO
Outperform
Oppenheimer upgrades Snap to Outperform amid post-earnings selloff
With Snap trading down 21% following last night's earnings report, Oppenheimer Jason Helfstein upgraded the shares to Outperform from Perform. The analyst has a $23 price target for the shares. Snap in premarket trading is down $4.72, or 21%, to $18.26. Numerous analysts ignored Snap's prospectus disclosure that suggested sequentially declining revenue in Q1, Helfstein tells investors in a research note. The company's products will continue to be made for "universal use, not tailored toward on-boarding older users," he adds.
WPM Wheaton Precious Metals
$20.99

-0.4 (-1.87%)

NAK Northern Dynasty
$1.73

-0.06 (-3.35%)

02/16/17
TDSI
02/16/17
UPGRADE
TDSI
Speculative Buy
Northern Dynasty upgraded to Speculative Buy from Hold at TD Securities
AAOI Applied Optoelectronics
$63.98

2.6 (4.24%)

05/05/17
RAJA
05/05/17
NO CHANGE
RAJA
Worries about Applied Optoelectronics competition overdone, says Raymond James
Raymond James analyst Simon Leopold believes that worries about Applied Optoelectronics' competition, which he believes have pressured the stock, are overdone. The analyst says that demand for data centers greatly exceed supply. He thinks that the company's "vertical integration, automation and product breadth" will help it contend against the competition. Leopold adds that the company is making progress on the development of its customer base and products. He raised his price target on the shares to $100 from $74 and keeps a Strong Buy rating.
05/05/17
ROTH
05/05/17
NO CHANGE
Target $70
ROTH
Buy
Applied Optoelectronics price target raised to $70 from $60 at Roth Capital
Roth Capital analyst Brian Alger raised his price target for Applied Optoelectronics to $70 from $60 after the company reported a "solid Q1," even better than implied by its pre-announcement. The analyst believes the company's profits will grow in spite of the competitive threats, and reiterates a Buy rating on the shares.
04/13/17
COWN
04/13/17
NO CHANGE
Target $75
COWN
Outperform
Applied Optoelectronics price target raised to $75 from $66 at Cowen
Cowen analyst Paul Silverstein raised his price target on Applied Optoelectronics to $75 from $66 following the company's preannouncement of strong Q1 revenues, gross margins, and earnings. Silverstein continues to see upside to both its operating model and shares. Silverstein reiterated his Outperform rating on Applied shares.
05/05/17
COWN
05/05/17
NO CHANGE
Target $94
COWN
Outperform
Applied Optoelectronics underappreciated and undervalued, says Cowen
Cowen analyst Paul Silverstein raised his operating forecasts for Applied Optoelectronics following better than expected Q1 results. The analyst continues to see a compelling risk/reward in the shares as the company gains new customer wins and makes product improvements. Silverstein reiterated his Outperform rating and raised his price target to $94 from $75 on Applied Optoelectronics shares.
KMX CarMax
$63.71

3.69 (6.15%)

04/05/17
MSCN
04/05/17
NO CHANGE
MSCN
CarMax Q1 tracking 'very strong,' says MScience
MScience said CarMax's Q1 is "very strong" with same-store-sales tracking to +8-10% versus consensus of +5%.
05/18/17
WEDB
05/18/17
UPGRADE
WEDB
Outperform
CarMax upgraded to Outperform from Neutral at Wedbush
05/18/17
WEDB
05/18/17
UPGRADE
WEDB
Outperform
CarMax upgraded on credit improvement at Wedbush
As noted earlier, Wedbush upgraded CarMax to Outperform from Neutral. Analyst Seth Basham says that the company's CAF credit losses will probably rise less in 2017 than in 2016, reducing "the risk of a credit-driven blowout." He also believes that the company's core business will continue to be strong. Target to $70 from $60.
05/18/17
05/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Progressive (PGR) upgraded to Hold from Sell at Deutsche Bank with analyst Joshua Shanker saying his concerns over the company's margins "are not longer apt" and that sees no catalyst to the downside. 2. Shake Shack (SHAK) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying the valuation at current share levels is attractive given Shake Shack's "industry-leading growth trajectory. 3. CarMax (KMX) upgraded to Outperform from Neutral at Wedbush with analyst Seth Basham saying the company's CAF credit losses will probably rise less in 2017 than in 2016, reducing "the risk of a credit-driven blowout." 4. Bank of Montreal (BMO) upgraded to Buy from Neutral at Citi with analyst Ian Sealey citing the recent pullback in the shares of Canadian banks as he sees "strong" book value and dividend growth over the longer term. 5. BioLineRx (BLRX) upgraded to Buy from Hold at Maxim with analyst Jason Kolbert saying the company is now closer to being a pivotal company after announcing it will initiate a Phase 3 program for BL-8040 in stem cell mobilization later this year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SHLD Sears
$7.72

-0.24 (-3.02%)

04/07/17
BERN
04/07/17
NO CHANGE
BERN
Best Buy tailwinds from competitor problems won't increase, says Bernstein
Bernstein analyst Brandon Fletcher says that Best Buy (BBY) bulls expect the company to benefit from the demise of competitors such as Sears (SHLD) and hhgregg. however, the analyst says that Best Buy has been benefiting form the demise of competitors for five years, so the tailwind it's getting from this source should not significantly increase. The analyst adds that other retailers, including Amazon (AMZN) and Wal-Mart (WMT), are also gaining share. He keeps an Underperform rating on Best Buy.
03/27/17
PIPR
03/27/17
UPGRADE
Target $55
PIPR
Overweight
Best Buy upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Peter Keith upgraded Best Buy (BBY) to Overweight and raised his price target for the shares to $55 from $45. Store closures from hhgregg and potentially Sears (SHLD) could lift Best Buy's comp sales by 2%, Keith tells investors in a research note. Further, the upcoming iPhone and Samsung Galaxy Note launches should bring a "strong smartphone upgrade cycle," the analyst contends.
02/10/17
SUSQ
02/10/17
INITIATION
Target $4
SUSQ
Neutral
Sears initiated with a Neutral at Susquehanna
Target $4.
01/03/17
RBCM
01/03/17
DOWNGRADE
RBCM
Sector Perform
Seritage Growth Properties downgraded on Sears headwinds at RBC Capital
As noted earlier, RBC Capital downgraded Seritage Growth (SRG) to Sector Perform from Outperform. Analyst Wes Golladay says that the stock's upside is limited by headwinds faced by the REIT's top tenant, Sears (SHLD). He adds that the 6.5%-8% interest rate of the company's new loan from ESL is high. Target to $48 from $62.
EXAS Exact Sciences
$31.03

0.7 (2.31%)

05/15/17
CHLM
05/15/17
NO CHANGE
Target $35
CHLM
Buy
Exact Sciences should be bought on weakness, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich notes that Exact Sciences are down following the short report issued by Citron Research. The analyst believes the issues raised in the short report are relatively consistent with the past issues raised on Exact Sciences over the years. While Citron has raised some interesting points, rehashed some of the old short thesis and caused a lot of volatility in the stock, Ellich adds, he would be a buyer on weakness. The analyst reiterates a Buy rating and $35 price target on the shares.
05/16/17
JEFF
05/16/17
NO CHANGE
Target $35
JEFF
Buy
Exact Sciences short report offers nothing new, says Jefferies
Jefferies analyst Brandon Couillard sees nothing new on Exact Sciences in yesterday's short report from Citron Research. The analyst views the 4% selloff yesterday in Exact shares as a buying opportunity. Citron's report "broke no new ground" and "struck us as consistent with many of the same flawed arguments as prior efforts," Couillard tells investors in a research note. The analyst has a Buy rating on Exact Sciences with a $35 price target. The stock closed yesterday down $1.34 to $32.43.
05/16/17
COWN
05/16/17
NO CHANGE
Target $45
COWN
Outperform
Exact Sciences meeting fortified confidence in momentum, says Cowen
Cowen analyst Doug Schenkel recently held a series of meetings with Exact Sciences management and came away with fortified confidence in its momentum and outlook for upside relative to current Street expectations. Management believes the new provider additions rate is sustainable for the next few years. Schenkel reiterated his Outperform rating and $45 price target on Exact Sciences shares.
05/15/17
ADAM
05/15/17
NO CHANGE
Target $38
ADAM
Buy
Exact Sciences should be bought on weakness, says Canaccord
Canaccord analyst Mark Massaro notes that Exact Sciences' shares are off following a short report published by Citron Research, and followed by a 1-on-1 appearance between the lead author of the short report and Kevin Conroy, Chairman and CEO of Exact Sciences. However, the analyst believes the author's short report to be flawed in several key areas, namely when it stated that "Colonoscopy is the gold standard" and is perfectly sensitive, "Exact Sciences will never be profitable," Medicare pricing will decline, Exact Sciences "terminal value might be $0," "Cologuard is not effective," and that there is no operating leverage. Massaro reiterates a Buy rating and $38 price target on the shares and says he is a buyer on weakness.

TODAY'S FREE FLY STORIES

PTCT

PTC Therapeutics

$16.99

-0.8 (-4.50%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Conference/Events
Breaking Conference/Events news story on PTC Therapeutics »

FDA PDUFA Date for PTC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

  • 06

    Nov

GLW

Corning

$30.01

-0.05 (-0.17%)

07:18
10/24/17
10/24
07:18
10/24/17
07:18
Earnings
Corning reports Q3 core EPS 43c, consensus 41c »

Reports Q3 GAAP revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

HYGS

Hydrogenics

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Conference/Events
TMX Group to hold a conference »

TSX Industrial &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 16

    Nov

THR

Thermon Group

$21.40

0.4 (1.90%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Thermon Group analyst commentary  »

Thermon Group price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$59.15

-0.3 (-0.50%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Pegasystems analyst commentary  »

Pegasystems should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$386.58

-3.12 (-0.80%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Technical Analysis
Technical View: Sherwin-Williams slips lower after results »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

, FPAY

FlexShopper

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Conference/Events
Stephens to hold meetings at conference »

Stephens Hosted Company…

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

FPAY

FlexShopper

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CTMX

CytomX Therapeutics

$20.04

-0.12 (-0.60%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
CytomX Therapeutics initiated  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$171.27

-3.71 (-2.12%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Periodicals
Facebook faces EU-wide privacy fights after top court setback, Bloomberg says »

Facebook may faces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

HFC

HollyFrontier

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
HollyFrontier rating change  »

HollyFrontier downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PBF

PBF Energy

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
PBF Energy rating change  »

PBF Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPX

Louisiana-Pacific

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
Louisiana-Pacific initiated  »

Louisiana-Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VLO

Valero

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Downgrade
Valero rating change  »

Valero downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

DK

Delek US

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Delek US rating change  »

Delek US upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ALDW

Alon USA Partners

$11.74

0.05 (0.43%)

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Alon USA Partners rating change  »

Alon USA Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Conference/Events
Drug Information Association to hold a conference »

Biosimilars Conference is…

PEBO

Peoples Bancorp

$33.03

-0.79 (-2.34%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Earnings
Peoples Bancorp reports Q3 EPS 60c, consensus 50c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

WY

Weyerhaeuser

$34.82

-0.46 (-1.30%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Initiation
Weyerhaeuser initiated  »

Weyerhaeuser initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ALXN

Alexion

$135.21

-3.81 (-2.74%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Recommendations
Alexion analyst commentary  »

Alexion could be up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 06

    Nov

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Hot Stocks
Breaking Hot Stocks news story on Pentair »

Pentair: Separation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees FY17 adjusted EPS $3.53, consensus $3.51 »

Sees FY17 sales $4.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees Q4 adjusted EPS approx. 93c, consensus 93c »

Sees Q4 revenue approx.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UFS

Domtar

$44.14

-0.23 (-0.52%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Initiation
Domtar initiated  »

Domtar initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ADDYY

adidas

$109.85

-0.45 (-0.41%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Initiation
adidas initiated  »

adidas initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$56.05

0.2 (0.36%)

07:11
10/24/17
10/24
07:11
10/24/17
07:11
Earnings
Asbury Automotive reports Q3 EPS $1.48 with items, consensus $1.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.